StockData
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc. (OVID) stock

OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.26+0.04 (+1.80%)

Close on Nov 18, 2026Market cap $441.37MP/E –Yield –

Ovid Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Ovid Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $1.58M, down 76.2% year over year. For fiscal 2025 it was $7.25M, up 1181.3% from the year before. The highest annual figure on record is $208.38M in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.25M+1181.3%
FY2024Dec 31, 2024$566.00K+44.4%
FY2023Dec 31, 2023$392.00K-73.9%
FY2022Dec 31, 2022$1.50M-99.3%
FY2021Dec 31, 2021$208.38M+1551.6%
FY2020Dec 31, 2020$12.62M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$733.00K-88.3%
Q1 FY2026Mar 31, 2026$0-100.0%
Q4 FY2025Dec 31, 2025$718.00K+844.7%
Q3 FY2025Sep 30, 2025$132.00K-23.7%
Q2 FY2025Jun 30, 2025$6.27M+3611.2%
Q1 FY2025Mar 31, 2025$130.00K-12.2%
Q4 FY2024Dec 31, 2024$76.00K-46.5%
Q3 FY2024Sep 30, 2024$173.00K+58.7%
Q2 FY2024Jun 30, 2024$169.00K+125.3%
Q1 FY2024Mar 31, 2024$148.00K+124.2%
Q4 FY2023Dec 31, 2023$142.00K+206.8%
Q3 FY2023Sep 30, 2023$109.00K+881.8%
Q2 FY2023Jun 30, 2023$75.00K–
Q1 FY2023Mar 31, 2023$66.00K-95.4%
Q4 FY2022Dec 31, 2022$46.28K–
Q3 FY2022Sep 30, 2022$11.10K–
Q2 FY2022Jun 30, 2022$0–
Q1 FY2022Mar 31, 2022$1.45M-99.3%
Q4 FY2021Dec 31, 2021$0-100.0%
Q3 FY2021Sep 30, 2021$0-100.0%
Q2 FY2021Jun 30, 2021$0–
Q1 FY2021Mar 31, 2021$208.38M–
Q4 FY2020Dec 31, 2020$5.70M–
Q3 FY2020Sep 30, 2020$6.91M–

More Ovid Therapeutics figures

See a number that looks wrong?